Jasper Therapeutics Announces Preclinical Data Presentations At American Academy of Allergy, Asthma, and Immunology Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Jasper Therapeutics announced its participation in the American Academy of Allergy, Asthma, and Immunology Annual Meeting with presentations on preclinical data for Briquilimab, an Anti-CD117 antibody. The data shows Briquilimab's potential in preventing systemic anaphylaxis, allergic asthma, and anaphylactoid drug reactions in mice models. The presentations are scheduled for February 23-25, 2024.
February 05, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jasper Therapeutics' announcement of presenting preclinical data on Briquilimab at the AAAAI Meeting may positively influence investor perception.
Presenting positive preclinical data at a prestigious conference can significantly boost investor confidence in Jasper Therapeutics' research and development capabilities, potentially leading to a positive short-term impact on its stock price. The focus on Briquilimab's potential in treating allergies and asthma, conditions with a high prevalence, underscores the significance of this development.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90